This statistic displays the top pharmaceutical R&D projects based on net present value, as of December 2024. According to the source, the top R&D project was Novo Nordisk's fixed-dose combination for type 2 diabetes and obesity Cagrisema, with a net present value of over 87 billion U.S. dollars at that time.
Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024
(in billion U.S. dollars)
Product (Company)
NPV in billion U.S. dollars
Cagrisema (Novo Nordisk)
87.3
Retatrutide (Eli Lilly)
38.6
Orforglipron (Eli Lilly/Chugai)
37.9
MariTide (Amgen)
31.4
Sonelokimab (Moonlake Immunotherapeutics)
8
Olpasiran (Amgen)
7.9
Ivonescimab (Akeso/Summit)
7.2
05101520253035404550556065707580859095100
Add this content to your personal favorites. These can be accessed from the favorites menu in the main navigation.
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Learn more about how Statista can support your business.
Evaluate Vantage. (January 2, 2025). Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024 (in billion U.S. dollars) [Graph]. In Statista. Retrieved May 03, 2025, from https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate Vantage. "Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024 (in billion U.S. dollars)." Chart. January 2, 2025. Statista. Accessed May 03, 2025. https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate Vantage. (2025). Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: May 03, 2025. https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate Vantage. "Selected Top Pharmaceutical R&d Projects Based on Net Present Value (Npv) as of December 2024 (in Billion U.S. Dollars)." Statista, Statista Inc., 2 Jan 2025, https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/
Evaluate Vantage, Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024 (in billion U.S. dollars) Statista, https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/ (last visited May 03, 2025)
Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2024 (in billion U.S. dollars) [Graph], Evaluate Vantage, January 2, 2025. [Online]. Available: https://www.statista.com/statistics/973453/most-valuable-randd-projects-by-npv/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
